Back to top

Image: Bigstock

Roche Holding AG

Read MoreHide Full Article

Roche continues to face generic competition for some of its drugs like Pegasys, Xeloda and Valcyte. In addition, possibility of stiff competition from biosimilars looms large on some of Roche’s key drugs such as Avastin, Rituxan and Herceptin over the long term. The biosimilar versions of MabThera and Herceptin are expected to enter the market in the second half of 2017, which will be followed by that of Avastin. On the diagnostics front, Roche is facing a challenging business environment as sales in the Diabetes Care unit continued to decline due to pricing pressure in the U.S. along with reimbursement issues. Roche has underperformed the Zacks classified Large Cap Pharmaceuticals industry in the year-to-date period. In fact, the stock has lost 17.6% during this period, compared with a drop of 6.1% for the industry.

 


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Roche Holding AG (RHHBY) - free report >>

Published in